Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-κB activation

Cancer Research

Volumn 61, Issue 10, 2001, Pages 4160-4168

  Hsu, Tin Chen ^a   Nair, Rajalakashimi ^b   Tulsian, Preety ^b   Camalier, Corinne E ^b   Hegamyer, Glenn A ^b   Young, Matthew R ^b   Colburn, Nancy H ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EPIDERMIS CELL; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; TRANSACTIVATION; TUMOR PROMOTION;

ANIMALS; CARCINOGENS; CELL LINE; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; DNA; DNA-BINDING PROTEINS; HUMANS; I-KAPPA B PROTEINS; MICE; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; SKIN; TETRADECANOYLPHORBOL ACETATE; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035872492     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis
2. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes
3. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis
4. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells
5. Tumour promoter induces anchorage independence irreversibly
6. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells
7. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation
8. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation
9. Multistage carcinogenesis in the skin
10. Inhibitors of both nuclear factor-κB and activator protein-1 activation block the neoplastic transformation response
11. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: Mitogen-resistant variants are sensitive to promotion
12. Phorbol diester and epidermal growth factor receptors in 12-O-tetradecanoylphorbol-13-acetate-resistant and -sensitive mouse epidermal cells
13. Activator protein-1 (AP-1)-and nuclear factor-κB (NF-κB)-dependent transcriptional events in carcinogenesis
14. Use of mouse JB6 cells to identify molecular targets and novel agents for prevention of carcinogenesis
15. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation
16. c-jun and multistage carcinogenesis: Association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation
17. Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformation
18. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice
19. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes
20. Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes
21. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion
22. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function
23. Multiple nuclear factors interact with the immunoglobulin enhancer sequences
24. Rel/NF-κB and IκB proteins: An overview
25. The N-terminal domain of IκBα masks the nuclear localization signal(s) of p50 and c-Rel homodimers
26. Mechanisms by which IκB proteins control NF-κB activity
27. Rel/NF-κB/IκB family: Intimate tales of association and dissociation
28. Identification of a naturally occurring transforming variant of the p65 subunit of NF-κB
29. Functional characterization of the NF-κB p65 transcriptional activator and an alternatively spliced derivative
30. The NF-κB and IκB proteins: New discoveries and insights
31. Disruption of IκBα regulation by antisense RNA expression leads to malignant transformation
32. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation
33. Rel/NF-κB/IκB proteins and cancer
34. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression
35. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death
36. Rel NF-κB and IκB factors in oncogenesis
37. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer
38. Suppression of TNF-α-induced apoptosis by NF-κB
39. Rel/NF-κB/IκB family: Intimate tales of association and dissociation
40. Induced expression of dominant negative cJun down regulates NFκB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes
41. Failure of the splicing variant p65 delta of the NF-κB subunit p65 to transform fibroblasts
42. Transactivation domain 2 (TA2) of p65 NF-κB
43. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element
44. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse B6 cells
45. The NF-κB transcription factor in oncogenesis
46. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB
47. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300